Journal of the American Academy of Dermatology
Volume 55, Issue 6 , Pages 968-974 , December 2006

Localized panniculitis secondary to subcutaneous glatiramer acetate injections for the treatment of multiple sclerosis: A clinicopathologic and immunohistochemical study

  • Luis Miguel Soares Almeida, MD

      Affiliations

    • From the Departments of Dermatology
    • ,
  • Luis Requena, MD

      Affiliations

    • Department of Dermatology, Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain
    • Corresponding Author InformationReprint requests: Luis Requena, MD, Department of Dermatology, Fundación Jiménez Díaz, Avda. Reyes Católicos 2, 28040-Madrid, Spain.
    • ,
  • Heinz Kutzner, MD

      Affiliations

    • Dermatohistopathologische Gemeinschaftspraxis, Friedrichshafen, Germany
    • ,
  • Jorge Angulo, MD

      Affiliations

    • Department of Dermatology, Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain
    • ,
  • Joao de Sa, MD

      Affiliations

    • Neurology, Hospital de Santa Maria, Universidade de Lisboa, Portugal
    • ,
  • Joao Pignatelli, MD

      Affiliations

    • From the Departments of Dermatology

,Accepted 24 April 2006.

References 

  1. Bornstein MB, Miller A, Slagle S, Weitzman M, Crystal H, Drexler E, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med. 1987;317:408–414
  2. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis. Neurology. 1995;45:1268–1276
  3. Drago F, Brusati C, Mancardi G, Murialdo A, Rebora A. Localized lipoatrophy after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis. Arch Dermatol. 1999;135:1277–1278
  4. Mancardi GL, Murialdo A, Drago F, Brusati C, Croce R, Inglese M, et al. Localized lipoatrophy after prolonged treatment with copolymer 1. J Neurol. 2000;247:220–221
  5. Hwang L, Orengo I. Lipoatrophy associated with glatiramer acetate injections for the treatment of multiple sclerosis. Cutis. 2001;68:287–288
  6. Soós N, Shakery K, Mrowietz U. Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis. Am J Clin Dermatol. 2004;5:357–359
  7. Edgar CM, Brunet DG, Fenton P, McBride EV, Green P. Lipoatrophy in patients with multiple sclerosis on glatiramer acetate. Can J Neurol Sci. 2004;31:58–63
  8. Copaxone. [package insert] Kansas City, MO: TEVA Marion Partners; 2000;
  9. Fridkis-Hareli M, Teitelbaum D, Guverich E, Pecht I, Brautbar C, Kwon OJ, et al. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells–specificity and promiscuity. Proc Natl Acad Sci U S A. 1994;91:4872–4876
  10. Miller A, Shapiro S, Gershtein R, Kinarty A, Rawashdeh H, Honigman S, et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone). Implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol. 1998;92:113–121
  11. Ziemssen T, Neuhaus O, Farina C, Hartung HP, Hohlfeld R. Behandlung der Multiplen Sklerosen mit Glatiramer-Azetat. Nervenarzt. 2002;73:321–331
  12. Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. J Neuroimmunol. 2000;107:161–166
  13. Johnson KP. A review of the clinical efficacy profile of copolymer 1: new US phase III trial data. J Neurol. 1996;243(Suppl):S3–S7
  14. Requena L, Sánchez Yus E. Panniculitis, part II: mostly lobular panniculitis. J Am Acad Dermatol. 2001;45:325–361

 Funding sources: None.Conflicts of interest: None identified.

PII: S0190-9622(06)01276-X

doi: 10.1016/j.jaad.2006.04.069

Journal of the American Academy of Dermatology
Volume 55, Issue 6 , Pages 968-974 , December 2006

Article Tools

* Image Usage & Resolution